[go: up one dir, main page]

HUP0400703A2 - Csökkentett immunogenitású módosított eritropoietin (EPO) - Google Patents

Csökkentett immunogenitású módosított eritropoietin (EPO)

Info

Publication number
HUP0400703A2
HUP0400703A2 HU0400703A HUP0400703A HUP0400703A2 HU P0400703 A2 HUP0400703 A2 HU P0400703A2 HU 0400703 A HU0400703 A HU 0400703A HU P0400703 A HUP0400703 A HU P0400703A HU P0400703 A2 HUP0400703 A2 HU P0400703A2
Authority
HU
Hungary
Prior art keywords
modified
subject
epo
polypeptides
modified erythropoietin
Prior art date
Application number
HU0400703A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Tim Jones
Stephen Williams
Original Assignee
Merck Patent Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh. filed Critical Merck Patent Gmbh.
Publication of HUP0400703A2 publication Critical patent/HUP0400703A2/hu
Publication of HUP0400703A3 publication Critical patent/HUP0400703A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát olyan polipeptidek képezik, amelyek - elsősorbanterápiás célból - speciálisan embereknek adagolhatók. A találmányszerinti polipeptidek módosított polipeptidek, mely módosításeredményeként a polipeptid - embereknek történő adagolása esetén -kevésbé hajlamos immunreakció kiváltására. Közelebbről, a találmánytárgyát humán eritropoietin (EPO) módosított változatai képezik, melyEPO-proteinváltozatok in vivo alkalmazáskor lényegében nem immunogénekvagy kevésbé immunogének, mint a megfelelő, módosítás nélküli alakjuk.Szintén a találmány tárgyát képezik a nem módosított proteinbőlszármazó T-sejtepitóp peptidek, valamint azok alkalmazása csökkentimmunogenitású, módosított eritropoietin-változatok előállítására. Atalálmány tárgyát képezik továbbá a találmány szerinti módosítotteritropoietin-molekulákat kódoló DNS-ek, a találmány szerintimódosított eritropoietinmolekulákat tartalmazó gyógyászatikészítmények, valamint eljárások a módosított eritropoietin-molekulákelőállítására. Ó
HU0400703A 2001-02-06 2002-02-05 Modified erythropoietin (epo) with reduced immunogenicity HUP0400703A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102615 2001-02-06
EP01103954 2001-02-19
PCT/EP2002/001174 WO2002062843A2 (en) 2001-02-06 2002-02-05 Modified erythropoietin (epo) with reduced immunogenicity

Publications (2)

Publication Number Publication Date
HUP0400703A2 true HUP0400703A2 (hu) 2004-06-28
HUP0400703A3 HUP0400703A3 (en) 2006-06-28

Family

ID=26076459

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400703A HUP0400703A3 (en) 2001-02-06 2002-02-05 Modified erythropoietin (epo) with reduced immunogenicity

Country Status (12)

Country Link
US (1) US20040063917A1 (hu)
EP (1) EP1357933A2 (hu)
JP (1) JP2004522445A (hu)
KR (1) KR20030074784A (hu)
CN (1) CN1514733A (hu)
BR (1) BR0207015A (hu)
CA (1) CA2437272A1 (hu)
HU (1) HUP0400703A3 (hu)
MX (1) MXPA03006990A (hu)
PL (1) PL362396A1 (hu)
RU (1) RU2003125654A (hu)
WO (1) WO2002062843A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060003853A (ko) * 2002-08-09 2006-01-11 메르크 파텐트 게엠베하 에리트로포이에틴 내의 ｔ-세포 에피토프
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2521273A1 (en) * 2003-04-02 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
WO2006029094A2 (en) * 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US8071554B2 (en) 2005-08-05 2011-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
EP2167528B1 (en) * 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modified toxins
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
ATE548381T1 (de) * 2008-05-29 2012-03-15 Hanall Biopharma Co Ltd Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
MX2016000448A (es) * 2013-07-17 2016-05-12 Araim Pharmaceuticals Inc Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
ATE319745T1 (de) * 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
BR9812267B1 (pt) * 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Also Published As

Publication number Publication date
CN1514733A (zh) 2004-07-21
HUP0400703A3 (en) 2006-06-28
RU2003125654A (ru) 2005-03-10
PL362396A1 (en) 2004-11-02
MXPA03006990A (es) 2003-11-18
WO2002062843A2 (en) 2002-08-15
BR0207015A (pt) 2004-07-06
WO2002062843A3 (en) 2002-12-12
KR20030074784A (ko) 2003-09-19
JP2004522445A (ja) 2004-07-29
US20040063917A1 (en) 2004-04-01
EP1357933A2 (en) 2003-11-05
CA2437272A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
HUP0401534A2 (hu) Módosított humán IX. faktor
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
HK1126668A1 (en) Survivin-derived peptides and use thereof
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
HK1112367A1 (en) Survivin peptide vaccine
NO20110429L (no) Polypeptider og nukleinsyre-DNA for anvendelse innen medisin
PL371278A1 (en) Modified factor viii
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2002098360A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
HUP0303310A2 (hu) Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
BR0207945A (pt) Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
WO2003093298A3 (en) Immunogenic peptides
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
BR0211991A (pt) HormÈnio do crescimento humano modificado
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees